Also trades as: KZA.AX (ASX) · $vol 0M
KZIA NASDAQ
Kazia Therapeutics Limited
1W: -3.0%
1M: +16.4%
3M: +118.6%
YTD: +168.4%
1Y: +279.1%
3Y: -78.7%
5Y: -97.2%
$13.66
+0.49 (+3.72%)
Weekly Expected Move ±11.1%
$10
$12
$13
$15
$16
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$22.1M
52W Range3.3-17.4
Volume156,013
Avg Volume210,988
Beta2.23
Dividend—
Analyst Ratings
Company Info
CEOJohn Edwin Friend
Employees9
SectorHealthcare
IndustryBiotechnology
IPO Date1999-01-06
Websitekaziatherapeutics.com
Three International Towers
Sydney, NSW 2000
AU
Sydney, NSW 2000
AU
1300 787 272
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Short Interest in Novogen Limited (NASDAQ:KZIA) Decreases By 35.4%
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rao Sudha | 0 | — | 2026-04-13 | |
| Friend John E. II | 30,000 | $18.85 | 2026-03-18 | |
| Cain David | 5,000 | $19.00 | 2026-03-18 | |
| Cain David | 100,000 | $8.00 | 2026-03-18 | |
| Cain David | 100,000 | $0.67 | 2026-03-18 |